Clinical efficacy of pramipexole in the treatment of conditions other than Parkinson's disease

Reviews in Contemporary Pharmacotherapy

Volumn 12, Issue 1-2, 2001, Pages 87-104

  Becker, P M ^a   Corrigan, M H ^a   Kasper, S ^a   Lin, S C ^a   Montplaisir, J ^a   Szegedi, A ^a   Willner, P ^a  

^a Box 15 ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PRAMIPEXOLE;

ATTENTION DEFICIT DISORDER; BINDING AFFINITY; CLINICAL TRIAL; COCAINE DEPENDENCE; DEPRESSION; DRUG EFFICACY; DRUG INDICATION; DRUG RECEPTOR BINDING; HUMAN; IMPOTENCE; META ANALYSIS; PARKINSON DISEASE; PROGRESSIVE SUPRANUCLEAR PALSY; RESTLESS LEGS SYNDROME; REVIEW;

EID: 0034969790     PISSN: 09548602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (163)

1. Treatment of restless legs with gabapentin
2. 2 antagonists on male sexual behavior
3. Depression in Parkinson's disease must be properly diagnosed and treated to avoid serious morbidity
4. Augmentation of the restless legs syndrome with carbidopa/levodopa
5. Restless legs syndrome treatment with dopaminergic drugs
6. Periodic limb movements in sleep. State-dependent excitability of the spinal flexor reflex
7. Anxiolytic effects of dopamine receptor ligands. I. Involvement of dopamine autoreceptors
8. Dopaminergic agents in restless legs syndrome and periodic movements of sleep: Response and complications of extended treatment in 49 cases
9. Encouraging initial response of restless legs syndrome to pramipexole
10. Dopamine receptor agonists in the treatment of schizophrenia and major depression
11. Dopamine agonists in schizophrenia: A review
12. The treatment of the restless legs syndrome with clonazepam: A prospective controlled study
13. The effect of triazolam in increasing sleep continuity in patients with periodic leg movements and objective daytime sleepiness
14. Treatment of restless legs syndrome and periodic movements during sleep with L-dopa: A double-blind, controlled study
15. Psychiatric morbidity in patients with Parkinson's disease
16. Parkinsonism and depression
17. Alterations in cognitive performance and affect-arousal state during fluctuations in motor function in Parkinson's disease
18. Depression and disability in Parkinson's disease: A follow-up study of 132 cases
19. Cerebral generators involved in the pathogenesis of the restless legs syndrome
20. Limbicstriatal interactions in the reward process: Modulation by the dopaminergic system
21. 3 receptor test in vitro predicts decreased cocaine self-administration in rats
22. Major depression in Parkinson's disease and the mood response to intravenous methylphenidate: Possible role of the 'hedonic' dopamine synapse
23. Psychiatric disturbances in Parkinson's disease
24. Periodic arm movements in patients with the restless legs syndrome
25. Association of attention-deficit disorder and the dopamine transporter gene
26. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression
27. Depression and Parkinson's disease: A review
28. D-3 receptor agonists: Combined action neurologic and neuropsychiatric agents
29. Depression in patients with Parkinson's disease
30. Pramipexole in the augmentatiion of a selective serotonin reuptake inhibitor in the treatment of depression
31. Enhanced functional responsiveness of the dopaminergic system: The mechanism of anti-immobility effects of antidepressants in the behavioural despair test in the rat
32. Behavioral effects in rats of the putative dopamine D-3 receptor agonist 7-OH-DPAT: Comparsion with quinpirole and apomorphine
33. Triazolam treatment of periodic leg movements during sleep
34. An estimate of the incidence of depression in idiopathic Parkinson's disease
35. Pergolide and carbidopa/levodopa treatment of the restless legs syndrome and periodic leg movements of sleep in a consecutive series of patients
36. Restless legs: A clinical study
37. Depressive symptoms in Parkinson's disease: A comparison with disabled control subjects
38. Assessing anhedonia in psychiatric patients: The pleasure scale
39. The neurobiological substrates of depression in Parkinson's disease: A hypothesis
40. Sexual excitement and stretching-yawning induced by B-HT 920
41. Sexual attraction and copulation in male rats: Effects of the dopamine agonist SND 919
42. 2 dopamine receptor agonist
43. Role of brain serotonin and dopamine in male sexual behavior
44. A comparison of clinical and pathological features of young- and old-onset Parkinson's disease
45. Cardiovascular effects of antidepressant drugs
46. The mesocortical-prefrontal dopaminergic neurons
47. Clinical and biochemical manifestations of depression. Relation to the neurobiology of stress
48. Pramipexole in refractory bipolar depression
49. Depression in Parkinson's disease: A quantitative and qualitative analysis
50. Dopaminergic treatment of restless legs and rebound phenomenon
51. Preliminary examination of the comorbidity of anxiety and depression in Parkinson's disease
52. Dyskinesias while awake and periodic movements in sleep in restless legs syndrome: Treatment with opioids
53. Monoamine receptor systems and anxiety disorders
54. Parkinsonism: Onset, progression and mortality
55. Depression in Parkinson's disease
56. The pattern of depressive symptoms varies with progression of Parkinson's disease
57. Towards a better definition of restless legs syndrome
58. Anxiety disorders and Parkinson's disease
59. Progressive supranuclear palsy: Clinical features and responses to treatment in sixteen patients
60. Variable expression of Parkinson's disease: A base-line analysis of the DATATOP cohort
61. Increased spinal cord activity in patients with restless legs syndrome
62. Antiparkinsonian and antidepressant effects of high doses of bromocriptine: An independent comparison
63. Role of the dopaminergic system in depression
64. Early clinical results with the neuroleptic roxindole (EMD 49980) in the treatment of schizophrenia - An open study
65. Pramipexole as adjunct to haloperidol in schizophrenia. Safety and efficacy
66. Opioid treatment of periodic movements in sleep in patients without restless legs
67. Erste klinische erfahrungen mit dem neuen dopamin-autorezeptoragonisten SND 919
68. Endogenomorphic depression: A conceptual and terminological revision
69. Repeated administration of antidepressant drugs enhanced agonist affinity for mesolimbic D-2 receptors
70. Sleep and treatment prediction in endogenous depression
71. Parkinson's disease and depression: Psychometric properties of the beck depression inventory
72. Effect of pramipexole in treatment of resistant restless legs syndrome
73. Long-term use of pramipexole in the treatment of restless legs syndrome: A two-year follow-up
74. Is Parkinson's disease of early onset a separate disease entity?
75. Synergistic effect of pramipexole and sertraline in the forced swimming test
76. Antidepressant effects of pramipexole, a novel dopamine receptor agonist
77. Catecholaminergic systems in the medulla oblongata in parkinsonian syndromes: A quantitative immunohistochemical study in Parkinson's disease, progressive supranuclear palsy and striatonigral degeneration
78. Clinical and biochemical features of depression in Parkinson's disease
79. Depression, intellectual impairment and Parkinson's disease
80. Altered serotonin metabolism in depressed patients with Parkinson's disease
81. The relationship of serotonin to depression in Parkinson's disease
82. Mood changes and 'on-off' phenomena in Parkinson's disease
83. Parkinson's disease and anxiety: Comorbidity with depression
84. Psychiatric symptoms during L-dopa therapy for Parkinson's disease and their relationship to physical disability
85. Nocturnal myoclonus: Treatment efficacy of clonazepam and temazepam
86. Restless legs syndrome and periodic movements in sleep: Physiopathology and treatment with L-dopa
87. Clinical polysomnographic and genetic characteristics of restless legs syndrome: A study of 133 patients diagnosed with new standard criteria
88. Immobilization tests and periodic leg movements in sleep for the diagnosis of the restless leg syndrome
89. Pramipexole alleviates sensory and motor symptoms of restless legs syndrome
90. Restless legs syndrome improved by pramipexole. A double-blind randomized trial
91. Pramipexole in the treatment of restless legs syndrome: A follow-up study
92. Effects of moclobemide, a new generation reversible MAO-A inhibitor, in a novel animal model of depression
93. Dopaminergic mechanism of imipramine action in an animal model of depression
94. Reversal of stress-induced anhedonia by the atypical antidepressants, fluoxetine and maprotiline
95. Antidepressant-like actions of dopamine agonists in an animal model of depression
96. Exacerbation of psychosis by tricyclic antidepressants in delusional depression
97. Retrospective study of drug response in 87 patients with progressive supranuclear palsy
98. Mood swings associated with the 'on-off' phenomenon in Parkinson's disease
99. B-HT 920, a dopamine D2 agonist, in the treatment of negative symptoms of chronic schizophrenia
100. Iron status and restless legs syndrome in the elderly
101. The effect of the partial dopamine agonist terguride on negative symptoms in schizophrenics
102. Restless legs syndrome
103. Clinical correlates of 6-hydroxy-dopamine injections into A11 dopaminergic neurons in rats: A possible model for restless legs syndrome
104. Behavioural sensitization to a dopamine agonist is associated with recovery from stress-induced anhedonia
105. ZK91296, a partial agonist at benzodiazepine receptor
106. Periodic limb movements disorder and restless legs syndrome in children with attention-deficit hyperactivity disorder
107. 3-preferring agonist useful in treating Parkinson's disease
108. The effects of antidepressants and electroconvulsive shocks on the function of the mesolimbic dopamine system: A behavioural study
109. Adverse reactions of antidepressants in elderly patients
110. Behavioral despair in rats: A new model sensitive to antidepressant treatments
111. Effects of a dopamine agonist piribedil in depressed patients
112. Dopaminergic hypothesis for retarded depression: A symptom profile for predicting therapeutical responses
113. Effect of piribedil (ET-495) on plasma norepinephrine: Relationship to antidepressant response
114. A survey of antidepressant drug use in Parkinson's disease
115. Depression in patients with parkinsonism
116. Pramipexole treatment for cocaine cravings
117. The neuropsychiatry of brain iron
118. Reversal of antidepressant action by dopamine antagonists in an animal model of depression
119. Parkinson's disease with depression: A possible subgroup of idiopathic parkinsonism
120. Evidence for atypical depression in Parkinson's disease
121. Possible role of dopamine D1 receptors in the behavioral subsensitivity to dopamine agonists induced by chronic treatment with antidepressants
122. Role of cGMP in the mechanism of anxiolytic activity of U-78875
123. U-95666E: A potential anti-parkinsonian drug with anxiolytic activity
124. Dopamine receptor stimulation in the treatment of depression: Piribedil (ET-495)
125. Pergolide in the management of restless legs syndrome: An extended study
126. Organization of diencephalic neurons projecting to the spinal cord in the rat
127. Dopamine D2 receptor alteration in patients with periodic movements in sleep (nocturnal myoclonus)
128. Single photon emission tomography (SPET) imaging of dopamine D2 receptors in the course of dopamine replacement therapy in patients with nocturnal myoclonus syndrome
129. Pergolide: Treatment of choice in restless legs syndrome (RLS) and nocturnal myoclonus syndrome (NMS). A double-blind randomized crossover trial of pergolide versus L-dopa
130. Depression and cognitive impairment in Parkinson's disease
131. Depression in Parkinson's disease
132. Anxiety disorders in patients with Parkinson's disease
133. Pramipexole, a dopamine agonist, in major depression: Antidepressant effects and tolerability in an open study with multiple doses
134. Pramipexole, a dopamine agonist, in major depression: Antidepressant effects and tolerability in an open-label study with multiple doses
135. Possible stimulatory role of brain dopamine in the copulatory behaviour of male rats
136. Depression in Parkinson's disease: Reconciling physiological and psychological perspectives
137. Parkinson's disease and depression: A critical re-evaluation
138. Bromocriptine as antidepressant: Double-blind comparative study with imipramine in psychogenic and endogenous depression
139. Is it safe to combine a selective serotonin reuptake inhibitor with selegiline?
140. Circadian rhythms of patients with idiopathic restless legs syndrome
141. Response to opioids in three patients with restless legs syndrome
142. 16C-raclopride PET
143. REM sleep reduction effects on depression syndromes
144. Drug effects on REM sleep and on endogenous depression
145. Levodopa in restless legs
146. Long-term effect of dopaminergic drugs in restless legs syndrome: A 2-year follow-up
147. Bromocriptine and imipramine in endogenous depression: A double-blind controlled trial in outpatients
148. A double-blind randomized crossover trial of bromocriptine and placebo in restless legs syndrome
149. Depressive symptoms in Parkinson's patients referred for thalamotomy
150. Pramipexole in progressive supranuclear palsy
151. The mesolimbic dopamine system as a target for rapid antidepressant action
152. Validity, reliability and utility of the chronic mild stress model of depression: A 10-year review and evaluation
153. Reduction of sucrose preference by chronic mild stress and its restoration by a tricyclic antidepressant
154. Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole
155. Current issues in depression in Parkinson's disease